Gilead Sciences (GILDCL) Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
GILDCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$128,950.00 |
| 52 Week High | US$128,950.00 |
| 52 Week Low | US$91,700.00 |
| Beta | 0.40 |
| 1 Month Change | 0% |
| 3 Month Change | 63.23% |
| 1 Year Change | 63.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 77.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| GILDCL | CL Biotechs | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 63.2% | 0% | 0% |
Return vs Industry: GILDCL exceeded the CL Biotechs industry which returned 33% over the past year.
Return vs Market: GILDCL exceeded the CL Market which returned 33.3% over the past year.
Price Volatility
| GILDCL volatility | |
|---|---|
| GILDCL Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: GILDCL's share price has been volatile over the past 3 months compared to the CL market.
Volatility Over Time: GILDCL's weekly volatility has increased from 9% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Gilead Sciences, Inc. Fundamentals Summary
| GILDCL fundamental statistics | |
|---|---|
| Market cap | CL$154.58t |
| Earnings (TTM) | CL$7.62t |
| Revenue (TTM) | CL$26.38t |
Is GILDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILDCL income statement (TTM) | |
|---|---|
| Revenue | US$29.44b |
| Cost of Revenue | US$6.23b |
| Gross Profit | US$23.21b |
| Other Expenses | US$14.70b |
| Earnings | US$8.51b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.86 |
| Gross Margin | 78.84% |
| Net Profit Margin | 28.90% |
| Debt/Equity Ratio | 110.2% |
How did GILDCL perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/11 08:07 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gilead Sciences, Inc. is covered by 65 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |